HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Michael E. Jessen Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greilich, P. E. Articles by Jessen, M. E. Search for Related Content PubMed PubMed Citation Articles by Greilich, P. E. Articles by Jessen, M. E. Related Collections Extracorporeal circulation

J Thorac Cardiovasc Surg 2003;126:1498-1503
© 2003 The American Association for Thoracic Surgery

Cardiopulmonary support and physiology

Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of -aminocaproic acid and aprotinin

^a Departments of Anesthesiology and Pain Management, Dallas, Tex, USA
^b Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center-Dallas Veterans Affairs Medical Center, Dallas, Tex, USA

Received for publication January 17, 2003; revisions received March 25, 2003; revisions received April 17, 2003; accepted for publication April 24, 2003.

^* Address for reprints: Philip E. Greilich, MD, Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9068, USA
philip.greilich{at}utsouthwestern.edu

OBJECTIVES: Aprotinin is a broad-spectrum serine protease inhibitor that has been shown to attenuate the systemic inflammatory response in patients undergoing cardiac surgery with cardiopulmonary bypass. Although -aminocaproic acid is similar to aprotinin in its ability to inhibit excessive fibrinolysis (ie, plasmin activity and D-dimer formation), its ability to influence proinflammatory cytokine production remains unclear. This study was designed to compare the effects of -aminocaproic acid and aprotinin on plasma levels of interleukin-6 and interleukin-8 during and after cardiopulmonary bypass.

METHODS: Sixty patients were randomized in a double-blind fashion to receive -aminocaproic acid, aprotinin, or saline (placebo) in similar dosing regimens (loading dose, pump prime, and infusion). Arterial blood samples were collected before, during, and after cardiopulmonary bypass, and plasma levels of D-dimer, interleukin-6, and interleukin-8 were measured. Data were analyzed using repeated measures analysis of variance.

RESULTS: Both -aminocaproic acid and aprotinin administration resulted in significant (P < .05) reductions in D-dimer and interleukin-8 levels compared with saline. These reductions in D-dimer and interleukin-8 levels did not differ between the 2 drug-treated groups. The effect of these two antifibrinolytic agents on interleukin-6 was qualitatively similar to that noted with interleukin-8 but did not reach statistical significance.

CONCLUSIONS: When dosed in a similar manner, -aminocaproic acid seems to be as effective as aprotinin at reducing interleukin-6 and interleukin-8 levels in patients undergoing primary coronary artery bypass graft surgery. These data indicate that suppression of excessive plasmin activity or D-dimer formation or both may play an important role in the generation of proinflammatory cytokines during and after cardiopulmonary bypass.

This article has been cited by other articles:

				P. E. Greilich, M. E. Jessen, N. Satyanarayana, C. W. Whitten, G. A. Nuttall, J. M. Beckham, M. H. Wall, and J. F. Butterworth The Effect of Epsilon-Aminocaproic Acid and Aprotinin on Fibrinolysis and Blood Loss in Patients Undergoing Primary, Isolated Coronary Artery Bypass Surgery: A Randomized, Double-Blind, Placebo-Controlled, Noninferiority Trial Anesth. Analg., July 1, 2009; 109(1): 15 - 24. [Abstract] [Full Text] [PDF]

				M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]

				J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF]

				A. J. Rodrigues, P. R. B. Evora, S. Bassetto, P. M. Luciano, L. Alves Jr, A. S. Filho, and W. V. de Andrade Vicente Efficacy and Safety of Aprotinin Use for Reoperative Valvular Surgery Ann. Thorac. Surg., June 1, 2007; 83(6): 2060 - 2065. [Abstract] [Full Text] [PDF]

				M. Sander, C. von Heymann, V. v. Dossow, C. Spaethe, W. F. Konertz, U. Jain, and C. D. Spies Increased interleukin-6 after cardiac surgery predicts infection. Anesth. Analg., June 1, 2006; 102(6): 1623 - 1629. [Abstract] [Full Text] [PDF]

				D. Reis Miranda, D. Gommers, A. Struijs, R. Dekker, J. Mekel, R. Feelders, B. Lachmann, and A. J.J.C. Bogers Ventilation according to the open lung concept attenuates pulmonary inflammatory response in cardiac surgery Eur. J. Cardiothorac. Surg., December 1, 2005; 28(6): 889 - 895. [Abstract] [Full Text] [PDF]

				M. T. Ganter, S. Dalbert, K. Graves, R. Klaghofer, A. Zollinger, and C. K. Hofer Monitoring Activated Clotting Time for Combined Heparin and Aprotinin Application: An In Vitro Evaluation of a New Aprotinin-Insensitive Test Using SONOCLOT Anesth. Analg., August 1, 2005; 101(2): 308 - 314. [Abstract] [Full Text] [PDF]

				G. S. Aldea Invited commentary Ann. Thorac. Surg., June 1, 2005; 79(6): 2038 - 2039. [Full Text] [PDF]